Annovis Bio, Inc.
ANVSAnnovis Bio, Inc. in brief
Annovis Bio, Inc. is a listed company in the Biotechnology industry, based in California, USA. It was founded in 2008. Its market value was $63 M on 30 October 2026, which makes it the 20,449th largest listed company in the world and the 3,755th largest in the USA on this site. Maria-Luisa Maccecchini is its chief executive. Its shares trade under the symbol ANVS (NYSE).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Annovis Bio, Inc.
We are a late-stage clinical drug platform company addressing neurodegeneration, such as Alzheimer’s disease and Parkinson’s disease. We are developing our lead product candidate, buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. In several studies, buntanetap was observed to inhibit the synthesis of neurotoxic proteins — APP/Aβ, tau/phospho-tau, α-Synuclein and TDP43 — that are some of the main causes of neurodegeneration. High levels of neurotoxic proteins lead to reduced axonal transport, which is responsible for communication between and within nerve cells. When that communication is compromised, the immune system is activated and attacks the nerve cells, eventually killing them. We have observed in our completed clinical studies in AD and PD patients and pre-clinical studies in mice and rats that buntanetap lowered neurotoxic protein levels leading to improved axonal transport, reduced inflammation, lower nerve cell death and improved affected function.
From the company's annual report filed with the US SEC: read the report
Annovis Bio, Inc. timeline
- 2008
- 🏁· approximateFounded
- 2010
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2019
- ✎Renamed Annovis Bio, Inc.Formerly QR Pharma, Inc..
- 2020
- 🔔Initial public offering on NYSEFinal prospectus filed with the SEC on 30 January 2020; shares registered for exchange trading on 28 January 2020.
Events of Annovis Bio, Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,031 (Jan 2021) · #4,166 (Jan 2022) · #4,228 (Dec 2022) · #4,062 (Jul 2023) · #3,293 (Jan 2024) · #2,068 (Mar 2026) · #3,644 (Aug 2026) · #3,724 (Oct 2026) · #3,759 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 3.8×
- Free cash flow yield
- —
- Net margin
- —
- Operating margin
- —
- Return on equity
- -171.2%
- Liabilities / assets
- 20.1%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-30M | $-29M | — |
| Dec 2024 | — | — | $-27M | $-25M | — |
| Dec 2023 | — | — | $-45M | $-56M | — |
| Dec 2022 | — | — | $-26M | $-25M | — |
| Dec 2021 | — | — | $-15M | $-14M | — |
| Dec 2020 | — | — | $-7M | $-5M | — |
| Dec 2019 | — | — | $-2M | $-1M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-26M | — | — | $-1.40 | — |
| Dec 2024 | $-22M | — | — | $-2.31 | — |
| Dec 2023 | $-40M | — | — | $-6.23 | — |
| Dec 2022 | $-17M | — | — | $-3.10 | — |
| Dec 2021 | $-9M | — | — | $-1.90 | — |
| Dec 2020 | $-4M | — | — | $-0.87 | — |
| Dec 2019 | $-0M | — | — | $-3.51 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-9M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 5, 20268-KCurrent reportMaterial agreement · Regulation FD disclosure
- Nov 4, 20268-KCurrent reportResults of operations · Regulation FD disclosure · Other events
- Nov 4, 20268-KCurrent reportBylaws amended · Shareholder vote
- Oct 30, 20268-KCurrent reportListing notice · Regulation FD disclosure
- Oct 20, 20268-KCurrent reportOther events
- Sep 11, 2026DEF 14AProxy statement
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Aug 14, 20268-KCurrent reportResults of operations
- Jul 10, 20268-KCurrent reportOther events
- Jun 17, 20268-KCurrent reportShareholder vote
- May 20, 20268-KCurrent reportMaterial agreement · Regulation FD disclosure
- May 15, 202610-QQuarterly report · period to Mar 2026
Official filings of Annovis Bio, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-30 M
- Net income
- $-29 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $21 M
- Total liabilities
- $4 M
- Total equity
- $17 M
As of December-2025
Top 60 institutional investors in Annovis Bio, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Marshall Wace, LLP | 1,701,241 | -141,098 (-7.66%) | 3.99% | $2 M | Nov 13, 2026 |
| 2 | Vanguard Capital Management LLC | 1,581,689 | -65,633 (-3.98%) | 3.71% | $2 M | Nov 13, 2026 |
| 3 | Two Sigma Investments, LP | 748,234 | +168,663 (+29.10%) | 1.76% | $1 M | Nov 16, 2026 |
| 4 | Renaissance Technologies LLC | 736,027 | -266,173 (-26.56%) | 1.73% | $1 M | Nov 12, 2026 |
| 5 | Geode Capital Management, LLC | 324,422 | +40,605 (+14.31%) | 0.76% | $0 M | Nov 6, 2026 |
| 6 | BlackRock, Inc. | 245,096 | -4,760 (-1.91%) | 0.58% | $0 M | Nov 13, 2026 |
| 7 | Susquehanna International Group, LLP | 243,163 | +96,359 (+65.64%) | 0.57% | $0 M | Nov 16, 2026 |
| 8 | Vanguard Fiduciary Trust Co | 224,236 | +46,706 (+26.31%) | 0.53% | $0 M | Nov 13, 2026 |
| 9 | Gsa Capital Partners LLP | 218,398 | +168,494 (+337.64%) | 0.51% | $0 M | Nov 16, 2026 |
| 10 | Citadel Advisors LLC | 211,892 | -31,790 (-13.05%) | 0.50% | $0 M | Nov 16, 2026 |
| 11 | Morgan Stanley | 199,351 | +199,010 (+58360.70%) | 0.47% | $0 M | Nov 13, 2026 |
| 12 | UBS Group AG | 114,602 | +102,827 (+873.27%) | 0.27% | $0 M | Nov 10, 2026 |
| 13 | Greenwich Wealth Management LLC | 112,800 | +64,400 (+133.06%) | 0.26% | $0 M | Nov 12, 2026 |
| 14 | State Street Corp | 105,335 | +27,600 (+35.51%) | 0.25% | $0 M | Nov 12, 2026 |
| 15 | Northern Trust Corp | 68,070 | 0 (0.00%) | 0.16% | $0 M | Nov 16, 2026 |
| 16 | Sherry Group, Inc. | 57,270 | 0 (0.00%) | 0.13% | $0 M | Oct 9, 2026 |
| 17 | Wescott Financial Advisory Group, LLC | 41,607 | 0 (0.00%) | 0.10% | $0 M | Nov 9, 2026 |
| 18 | Bridgeway Capital Management, LLC | 37,114 | -563 (-1.49%) | 0.09% | $0 M | Nov 16, 2026 |
| 19 | Empowered Funds, LLC | 33,014 | New | 0.08% | $0 M | Nov 13, 2026 |
| 20 | Dakota Wealth Management | 29,000 | 0 (0.00%) | 0.07% | $0 M | Nov 12, 2026 |
| 21 | CWA Asset Management Group, LLC | 28,000 | -1 (0.00%) | 0.07% | $0 M | Oct 19, 2026 |
| 22 | Wells Fargo & Company/mn | 27,247 | -3,060 (-10.10%) | 0.06% | $0 M | Nov 16, 2026 |
| 23 | StoneX Group Inc. | 23,996 | +9,531 (+65.89%) | 0.06% | $0 M | Nov 3, 2026 |
| 24 | Sterling Investment Advisors, Ltd. | 23,416 | 0 (0.00%) | 0.06% | $0 M | Oct 27, 2026 |
| 25 | Wealthspire Advisors, LLC | 20,000 | 0 (0.00%) | 0.05% | $0 M | Nov 13, 2026 |
Show all 60: investors 26 to 60
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Nicholson Wealth Management Group, LLC | 20,000 | New | 0.05% | $0 M | Nov 9, 2026 |
| 27 | Jpmorgan Chase & Co | 19,900 | +4,681 (+30.76%) | 0.05% | $0 M | Nov 12, 2026 |
| 28 | Gill Capital Partners, LLC | 18,579 | 0 (0.00%) | 0.04% | $0 M | Oct 13, 2026 |
| 29 | Robertson Stephens Wealth Management, LLC | 18,579 | 0 (0.00%) | 0.04% | $0 M | Oct 16, 2026 |
| 30 | R Squared Ltd | 17,698 | New | 0.04% | $0 M | Nov 6, 2026 |
| 31 | Squarepoint Ops LLC | 16,769 | New | 0.04% | $0 M | Nov 9, 2026 |
| 32 | Quadcap Wealth Management, LLC | 16,110 | 0 (0.00%) | 0.04% | $0 M | Nov 2, 2026 |
| 33 | Bank of New York Mellon Corp | 15,476 | 0 (0.00%) | 0.04% | $0 M | Nov 5, 2026 |
| 34 | Tower Research Capital LLC (TRC) | 15,217 | New | 0.04% | $0 M | Nov 16, 2026 |
| 35 | Vanguard Global Advisers, LLC | 11,190 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 36 | RKL Wealth Management LLC | 10,000 | 0 (0.00%) | 0.02% | $0 M | Oct 16, 2026 |
| 37 | Wilmington Savings Fund Society, FSB | 9,393 | 0 (0.00%) | 0.02% | $0 M | Oct 23, 2026 |
| 38 | Osaic Holdings, Inc. | 6,640 | +6,430 (+3061.90%) | 0.02% | $0 M | Nov 12, 2026 |
| 39 | Royal Bank Of Canada | 6,600 | +1,000 (+17.86%) | 0.02% | $0 M | Nov 16, 2026 |
| 40 | Arax Advisory Partners | 6,500 | 0 (0.00%) | 0.02% | $0 M | Nov 12, 2026 |
| 41 | Gallacher Capital Management LLC | 5,705 | 0 (0.00%) | 0.01% | $0 M | Oct 30, 2026 |
| 42 | Covestor Ltd | 4,863 | +229 (+4.94%) | 0.01% | $0 M | Oct 30, 2026 |
| 43 | PNC Financial Services Group, Inc. | 2,960 | +2,600 (+722.22%) | 0.01% | $0 M | Nov 6, 2026 |
| 44 | Pinnacle Financial Group, Inc. | 2,400 | — | 0.01% | $0 M | Nov 16, 2026 |
| 45 | CoreCap Advisors, LLC | 2,101 | 0 (0.00%) | 0.00% | $0 M | Oct 8, 2026 |
| 46 | Nuveen, LLC | 1,861 | New | 0.00% | $0 M | Nov 10, 2026 |
| 47 | SBI Securities Co., Ltd. | 1,572 | +25 (+1.62%) | 0.00% | $0 M | Oct 22, 2026 |
| 48 | Keating Financial Advisory Services, Inc. | 1,082 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 49 | Rockefeller Capital Management L.P. | 1,000 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 50 | DiNuzzo Private Wealth, Inc. | 1,000 | 0 (0.00%) | 0.00% | $0 M | Oct 16, 2026 |
| 51 | Bokf, NA | 555 | 0 (0.00%) | 0.00% | $0 M | Oct 27, 2026 |
| 52 | Steward Partners Investment Advisory, LLC | 500 | -1,345 (-72.90%) | 0.00% | $0 M | Nov 13, 2026 |
| 53 | Rialto Wealth Management, LLC | 483 | +214 (+79.55%) | 0.00% | $0 M | Nov 16, 2026 |
| 54 | Larson Financial Group LLC | 300 | 0 (0.00%) | 0.00% | $0 M | Nov 5, 2026 |
| 55 | IFP Advisors, Inc | 110 | 0 (0.00%) | 0.00% | $0 M | Oct 16, 2026 |
| 56 | Global Retirement Partners, LLC | 100 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 57 | Caitong International Asset Management Co., Ltd | 52 | +46 (+766.67%) | 0.00% | $0 M | Oct 29, 2026 |
| 58 | Northwestern Mutual Wealth Management Co | 20 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 59 | Russell Investments Group, Ltd. | 1 | New | 0.00% | $0 M | Nov 6, 2026 |
| 60 | Blue Trust, Inc. | 1 | New | 0.00% | $0 M | Oct 15, 2026 |
Mutual funds holding Annovis Bio, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.22 M | $2 M | 2.9% | <0.01% | +106% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 393,887 | $1 M | 0.92% | <0.01% | +55% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 123,461 | $0 M | 0.29% | <0.01% | +1.0% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 103,332 | $0 M | 0.24% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 34,459 | $0 M | 0.08% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 33,419 | $0 M | 0.08% | <0.01% | +8.6% | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 33,577 | $0 M | 0.08% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 20,994 | $0 M | 0.05% | <0.01% | +59% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 12,723 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 6,991 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 557 | $0 M | <0.01% | <0.01% | +12% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 11 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Annovis Bio, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Michael B. HoffmanDirector | Buy | +5.00 M | $1.000 | $5.0 M | 8.36 M | Form 4 |
| filed | Michael B. HoffmanDirector | Buy | +2,562 | $1.750 | $4 K | 3.29 M | Form 4 |
| filed | Michael B. HoffmanDirector | Buy | +18,849 | $1.800 | $34 K | 3.31 M | Form 4 |
| filed | Michael B. HoffmanDirector | Buy | +54,933 | $1.900 | $104 K | 3.36 M | Form 4 |
| filed | Michael B. HoffmanDirector | Buy | +713,800 | $2.100 | $1.5 M | 3.29 M | Form 4 |
| filed | Michael B. HoffmanDirector | Buy | +30,000 | $4.340 | $130 K | 2.56 M | Form 4 |
| filed | Michael B. HoffmanDirector | Buy | +15,000 | $4.240 | $64 K | 2.57 M | Form 4 |
| filed | Michael B. HoffmanDirector | Buy | +1,489 | $4.130 | $6 K | 2.48 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Annovis Bio, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 37,968 shares at $1.02
- : 39,168 shares at $1.02
- : 42,825 shares at $0.98
- : 27,231 shares at $0.99
- : 18,312 shares at $1.06
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Annovis Bio, Inc. scorecard#
Passes 0 of the 10 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 3
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median3.8×Price to book 3.8× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.40 vs -2.31Diluted EPS -1.40 in fiscal 2025 against -2.31 the year before (report's currency).
- ✗Net income higher than five years earlier-$29 M-$29 M in fiscal 2025 against -$5 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$29 MNet income -$29 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-220.6%-220.6% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 1
- –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year68.0%Diluted shares up 68.0% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Annovis Bio, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | |
| Research and development | 25+26.1%— | 20−48.5%— | 39+135%— | 17+94.8%— | 8.5+178%— | 3.1+293%— | 0.8—— | |
| General and administrative | 4.5−33.1%— | 6.7+7.3%— | 6.2−30.6%— | 9.0+48.5%— | 6.1+68.9%— | 3.6+332%— | 0.8—— | |
| Operating expenses | 30+11.2%— | 27−40.7%— | 45+76.5%— | 26+75.5%— | 15+119%— | 6.6+314%— | 1.6—— | |
| Operating income | −30—— | −27—— | −45—— | −26—— | −15—— | −6.6—— | −1.6—— | |
| Interest and finance income | 0.7+111%— | 0.3−50.3%— | 0.7—— | — | — | — | — | |
| Other non-operating income (expense) | 0.8−60.0%— | 2.1—— | −11−6213%— | 0.2+265%— | 0.1−95.7%— | 1.2+91.7%— | 0.6—— | |
| Income before tax | — | — | −56—— | −25—— | −14—— | −5.5—— | −1.0—— | |
| Income tax | 0—— | — | — | — | — | — | 0—— | |
| Net income including minority interests | −29—— | −25—— | −56—— | −25—— | −14—— | −5.5—— | −1.0—— | |
| Net income attributable to shareholders | −29—— | −25—— | −56—— | −25—— | −14—— | −5.5—— | −1.0—— | |
| Earnings per share, basic | -1.40—— | -2.02—— | -6.23—— | -3.10—— | -1.90—— | -0.87—— | -3.51—— | |
| Earnings per share, diluted | -1.40—— | -2.31—— | -6.23—— | -3.10—— | -1.90—— | -0.87—— | -3.51—— | |
| Shares, weighted average (basic) | 21+68.7%— | 12+35.0%— | 9.0+10.5%— | 8.2+7.0%— | 7.6+20.9%— | 6.3—— | — | |
| Shares, weighted average (diluted) | 21+68.0%— | 12+35.6%— | 9.0+10.5%— | 8.2+7.0%— | 7.6+20.9%— | 6.3+2132%— | 0.3—— | |
| Balance sheet | ||||||||
| Cash and cash equivalents | 20+85.1%92.7% | 11+83.4%75.8% | 5.8−79.7%56.4% | 28−37.9%78.8% | 46+466%99.3% | 8.1+434489%99.4% | 0.0—0.2% | |
| Current assets | — | — | 10−71.7%100% | 36−21.7%100% | 46+467%100% | 8.1+986%100% | 0.7—66.9% | |
| Non-current assets | — | — | — | — | — | — | 0.4—33.1% | |
| Total assets | 21+51.4%100% | 14+36.4%100% | 10−71.7%100% | 36−21.7%100% | 46+467%100% | 8.1+627%100% | 1.1—100% | |
| Accounts payable | 2.6+12.3%12.3% | 2.3+78.4%16.6% | 1.3−67.4%12.7% | 4.0+476%11.0% | 0.7+101%1.5% | 0.3−72.3%4.2% | 1.2—110% | |
| Current liabilities | 3.6−6.3%17.2% | 3.9−9.3%27.9% | 4.3−44.4%41.9% | 7.7+411%21.4% | 1.5+160%3.3% | 0.6−71.2%7.1% | 2.0—180% | |
| Non-current liabilities | — | — | — | — | — | — | 0.6—54.2% | |
| Total liabilities | 4.2−8.4%20.1% | 4.6−74.3%33.2% | 18+133%176% | 7.7+411%21.4% | 1.5+160%3.3% | 0.6−77.9%7.1% | 2.6—234% | |
| Retained earnings | −164—−777% | −135—−968% | −110—−1080% | −54—−150% | −29—−62.4% | −14—−175% | −8.8—−786% | |
| Shareholders' equity | 17+81.0%79.9% | 9.3—66.8% | −7.8−127%−75.9% | 28−36.3%78.6% | 44+490%96.7% | 7.5—92.9% | −8.6—−768% | |
| Total liabilities and equity | 21+51.4%100% | 14+36.4%100% | 10−71.7%100% | 36−21.7%100% | 46+467%100% | 8.1+627%100% | 1.1—100% | |
| Shares outstanding | 27+92.3%— | 14+34.4%— | 11+28.9%— | 8.2+0.8%— | 8.1+17.5%— | 6.9+2339%— | 0.3—— | |
| Cash-flow statement | ||||||||
| Share-based compensation | 1.8−53.1%— | 3.8−17.1%— | 4.6−49.4%— | 9.2+94.8%— | 4.7+152%— | 1.9+21884%— | 0.0—— | |
| Cash from operating activities | −26—— | −22—— | −40—— | −17—— | −9.1—— | −4.0—— | −0.5—— | |
| Shares issued | — | 19+10.5%— | 17—— | — | 47+288%— | 12—— | — | |
| Cash from financing activities | 35+29.6%— | 27+53.9%— | 17+375888%— | 0.0−100.0%— | 47+288%— | 12+2618%— | 0.4—— | |
| Change in cash | 9.0+87.2%— | 4.8—— | −23—— | −17−146%— | 38+366%— | 8.1—— | −0.0—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 0—— | 0*—— | 0*—— | 0—— | 0*—— | 0*—— | 0*—— | 0—— | 0*—— | 0*—— | 0*—— | 0—— | 0*—— | |
| Research and development | 53+148%— | 16+151%— | 12+133%— | 17+234%— | 8.8*+75.1%— | 6.3+134%— | 5.2−10.8%— | 5.0−23.1%— | 5.0*−43.9%— | 2.7—— | 5.8—— | 6.5—— | 8.9*—— | |
| General and administrative | 5.8+10.4%— | 1.2+4.0%— | 2.4+114%— | 1.3+1.6%— | 1.0*−45.0%— | 1.1−32.6%— | 1.1−43.9%— | 1.3−1.8%— | 1.7*+12.9%— | 1.7—— | 2.0—— | 1.3—— | 1.5*—— | |
| Operating expenses | 59+121%— | 17+128%— | 14+129%— | 18+187%— | 9.7*+44.1%— | 7.4+69.5%— | 6.3−19.2%— | 6.3−19.6%— | 6.7*−35.5%— | 4.4—— | 7.8—— | 7.8—— | 10*—— | |
| Operating income | −59—— | −17—— | −14—— | −18—— | −9.7*—— | −7.4—— | −6.3—— | −6.3—— | −6.7*—— | −4.4—— | −7.8—— | −7.8—— | −10*—— | |
| Interest and finance income | 0.6−16.3%— | 0.1−44.3%— | 0.2−16.3%— | 0.1−26.6%— | 0.2*+32.8%— | 0.2+12.5%— | 0.2+637%— | 0.2+325%— | 0.1*+90.9%— | 0.1—— | 0.0—— | 0.0—— | 0.1*—— | |
| Other non-operating income (expense) | 7.3+299%— | 7.5+4256%— | −0.4−962%— | 0.4−45.6%— | −0.1*−115%— | 0.2—— | 0.1−98.1%— | 0.7−88.9%— | 0.9*—— | −8.3—— | 2.7—— | 6.7—— | −12*—— | |
| Income before tax | — | — | — | — | — | — | — | — | — | −13—— | −5.0—— | −1.1—— | −22*—— | |
| Income tax | 0—— | 0—— | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—— | — | 0—— | 0—— | 0—— | — | |
| Net income including minority interests | −52—— | −9.5*—— | −15*—— | −18—— | −9.8*—— | −7.3*—— | −6.2*—— | −5.5—— | −5.9*—— | −13*—— | −5.0*—— | −1.1—— | −22*—— | |
| Net income attributable to shareholders | −52—— | −9.5—— | −15—— | −18—— | −9.8*—— | −7.3—— | −6.2—— | −5.5—— | −5.9*—— | −13—— | −5.0—— | −1.1—— | −22*—— | |
| Earnings per share, basic | — | -0.22—— | -0.40—— | -0.63—— | — | -0.37—— | -0.32—— | -0.32—— | — | -0.97—— | -0.44—— | -0.10—— | — | |
| Earnings per share, diluted | — | -0.22—— | -0.40—— | -0.63—— | — | -0.37—— | -0.32—— | -0.32—— | — | -0.97—— | -0.44—— | -0.72r-0.72—— | — | |
| Shares, weighted average (basic) | 43+117%— | 43+117%— | 38+92.5%— | 28+59.8%— | — | 20+51.7%— | 19+72.3%— | 17+64.1%— | — | 13—— | 11—— | 11—— | — | |
| Shares, weighted average (diluted) | 43+117%— | 43+117%— | 38+92.5%— | 28+59.8%— | — | 20+51.7%— | 19+72.3%— | 17+61.0%— | — | 13—— | 11—— | 11r11—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 2.8—51.2% | 2.8−81.6%51.2% | 19+9.3%85.0% | 14−36.1%87.5% | 20+85.1%92.7% | 15+21.0%88.9% | 17+328%79.8% | 22+609%83.2% | 11+83.4%75.8% | 13—88.0% | 4.0—79.2% | 3.1—40.1% | 5.8—56.4% | |
| Current assets | — | — | — | — | — | — | — | — | — | — | — | 7.8—100% | 10—100% | |
| Total assets | 5.5—100% | 5.5−68.0%100% | 22+2.7%100% | 16−39.2%100% | 21+51.4%100% | 17+19.7%100% | 21+325%100% | 27+242%100% | 14+36.4%100% | 14—100% | 5.0—100% | 7.8—100% | 10—100% | |
| Accounts payable | 3.1—55.5% | 3.1+44.6%55.5% | 3.3+241%15.1% | 5.3+285%32.5% | 2.6+12.3%12.3% | 2.1−48.5%12.3% | 1.0−71.3%4.5% | 1.4−66.6%5.1% | 2.3+78.4%16.6% | 4.1—28.5% | 3.4—67.3% | 4.1—52.6% | 1.3—12.7% | |
| Current liabilities | 6.3—114% | 6.3+67.8%114% | 6.4+127%28.9% | 13+411%78.7% | 3.6−6.3%17.2% | 3.7−30.7%21.7% | 2.8−30.9%13.1% | 2.5−48.6%9.4% | 3.9−9.3%27.9% | 5.4—37.5% | 4.1—80.4% | 4.9—62.3% | 4.3—41.9% | |
| Total liabilities | 19—340% | 19+365%340% | 26+742%119% | 13+389%80.8% | 4.2−8.4%20.1% | 4.0−44.7%23.5% | 3.1−54.0%14.6% | 2.7−76.0%10.0% | 4.6−74.3%33.2% | 7.3—50.8% | 6.8—135% | 11—143% | 18—176% | |
| Retained earnings | −206—−3736% | −206—−3736% | −196—−890% | −181—−1116% | −164—−777% | −154—−895% | −147—−683% | −140—−525% | −135—−968% | −129—−898% | −116—−2306% | −111—−1425% | −110—−1080% | |
| Shareholders' equity | −13—−240% | −13−201%−240% | −4.3−123%−19.3% | 3.1−87.0%19.2% | 17+81.0%79.9% | 13+86.3%76.5% | 18—85.4% | 24—90.0% | 9.3—66.8% | 7.1—49.2% | −1.8—−34.7% | −3.4—−42.9% | −7.8—−75.9% | |
| Total liabilities and equity | 5.5—100% | 5.5−68.0%100% | 22+2.7%100% | 16−39.2%100% | 21+51.4%100% | 17+19.7%100% | 21+325%100% | 27+242%100% | 14+36.4%100% | 14—100% | 5.0—100% | 7.8—100% | 10—100% | |
| Shares outstanding | 43—— | 43+111%— | 43+119%— | 29+46.4%— | 27+92.3%— | 20+52.0%— | 19+66.2%— | 19+77.0%— | 14+34.4%— | 13—— | 12—— | 11—— | 11—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 2.5−14.4%— | 0.4−20.1%— | 1.6+224%— | 0.2−63.4%— | 0.4*−75.9%— | 0.4+13.1%— | 0.5−68.9%— | 0.5+37.0%— | 1.5*+68.0%— | 0.4—— | 1.6—— | 0.4—— | 0.9*—— | |
| Cash from operating activities | −56—— | −16*—— | −22*—— | −9.0—— | −8.9*—— | −3.5*—— | −5.1*—— | −8.1—— | −8.3*—— | −3.2*—— | −3.4*—— | −7.0—— | −9.4*—— | |
| Shares issued | — | — | — | — | — | — | — | — | 6.2*−25.4%— | 4.4*—— | 4.2*—— | 3.9—— | 8.3*—— | |
| Cash from financing activities | 43+57.2%— | 0.1*−92.2%— | 26*—— | 3.7−81.3%— | 13*+112%— | 1.6*−86.1%— | 0*−100%— | 20+348%— | 6.2*−29.3%— | 12*—— | 4.2*—— | 4.4—— | 8.8*—— | |
| Change in cash | −12−570%— | −16*—— | 4.5*—— | −5.3−145%— | 4.2*—— | −1.8*−121%— | −5.1*−693%— | 12—— | −2.1*—— | 8.6*—— | 0.9*—— | −2.6—— | −0.6*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Annovis Bio, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 2 · Directors and officers 5 · Material agreement 7 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Material agreement | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officersResults announced | 8-K | |
| Delisting noticeDirectors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Annovis Bio, Inc. compares in Biotechnology
- Market cap$63 M · higher than 29% of 726
- Price / book3.8× · lower than 40% of 534
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Annovis Bio, Inc.🇺🇸 | $63 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Annovis Bio, Inc.? Verify and update this profile — free
Show Annovis Bio, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.